Biomar Microbial Technologies の製品パイプライン分析2016

【英語タイトル】Biomar Microbial Technologies - Product Pipeline Review - 2016

Global Markets Directが出版した調査資料(DATA70209150)・商品コード:DATA70209150
・発行会社(調査会社):Global Markets Direct
・発行日:2016年12月21日
・ページ数:49
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥162,000見積依頼/購入/質問フォーム
Site LicenseUSD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD4,500 ⇒換算¥486,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Biomar Microbial Technologies – Product Pipeline Review – 2016
Summary

Global Markets Direct’s, ‘Biomar Microbial Technologies – Product Pipeline Review – 2016’, provides an overview of the Biomar Microbial Technologies’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Biomar Microbial Technologies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Biomar Microbial Technologies
- The report provides overview of Biomar Microbial Technologies including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Biomar Microbial Technologies’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Biomar Microbial Technologies’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Biomar Microbial Technologies’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Biomar Microbial Technologies
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Biomar Microbial Technologies’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Biomar Microbial Technologies Snapshot 7
Biomar Microbial Technologies Overview 7
Key Facts 7
Biomar Microbial Technologies – Research and Development Overview 8
Key Therapeutic Areas 8
Biomar Microbial Technologies – Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products – Monotherapy 12
Biomar Microbial Technologies – Pipeline Products Glance 13
Biomar Microbial Technologies – Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Biomar Microbial Technologies – Drug Profiles 15
IB-05202 – Drug Profile 15
Product Description 15
Mechanism Of Action 15
R&D Progress 15
IB-06202 – Drug Profile 16
Product Description 16
Mechanism Of Action 16
R&D Progress 16
IB-07A037 – Drug Profile 17
Product Description 17
Mechanism Of Action 17
R&D Progress 17
IB-07A081 – Drug Profile 18
Product Description 18
Mechanism Of Action 18
R&D Progress 18
IB-07A085 – Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
IB-08C175 – Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
IB-08C179 – Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
IB-09A0133 – Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
IB-09A149 – Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
IB-10A111 – Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
IB-10C179 – Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
IB-12A157 – Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Small Molecule 1 for Oncology – Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Small Molecule 2 for Oncology – Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Small Molecule 3 for Oncology – Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Small Molecules 4 for Oncology – Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecules for Aspergillosis and Candidiasis – Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Small Molecules for Bacterial Infections – Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecules for Glioblastoma – Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecules for Multi Drug Resistant Staphylococcus Aureus Infections – Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecules for Neuropathic Pain – Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecules for Tuberculosis – Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecules to Antagonize G-Protein-Coupled Receptors for Oncology – Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecules to Antagonize VEGF Receptor for Oncology – Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecules to Inhibit Kinase for Oncology – Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecules to Inhibit NIK for Multiple Sclerosis – Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecules to Inhibit tRNA for Bacterial Infections – Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Biomar Microbial Technologies – Pipeline Analysis 42
Biomar Microbial Technologies – Pipeline Products by Target 42
Biomar Microbial Technologies – Pipeline Products by Route of Administration 43
Biomar Microbial Technologies – Pipeline Products by Molecule Type 44
Biomar Microbial Technologies – Pipeline Products by Mechanism of Action 45
Biomar Microbial Technologies – Dormant Projects 46
Biomar Microbial Technologies – Locations And Subsidiaries 47
Head Office 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables
Biomar Microbial Technologies, Key Facts 7
Biomar Microbial Technologies - Pipeline by Indication, 2016 9
Biomar Microbial Technologies - Pipeline by Stage of Development, 2016 11
Biomar Microbial Technologies - Monotherapy Products in Pipeline, 2016 12
Biomar Microbial Technologies - Preclinical, 2016 13
Biomar Microbial Technologies - Discovery, 2016 14
Biomar Microbial Technologies - Pipeline by Target, 2016 42
Biomar Microbial Technologies - Pipeline by Route of Administration, 2016 43
Biomar Microbial Technologies - Pipeline by Molecule Type, 2016 44
Biomar Microbial Technologies - Pipeline Products by Mechanism of Action, 2016 45
Biomar Microbial Technologies - Dormant Developmental Projects,2016 46

List of Figures
Biomar Microbial Technologies - Pipeline by Top 10 Indication, 2016 9
Biomar Microbial Technologies - Pipeline by Stage of Development, 2016 11
Biomar Microbial Technologies - Monotherapy Products in Pipeline, 2016 12
Biomar Microbial Technologies - Pipeline by Target, 2016 42
Biomar Microbial Technologies - Pipeline by Molecule Type, 2016 44
Biomar Microbial Technologies - Pipeline Products by Mechanism of Action, 2016 45

★調査レポート[Biomar Microbial Technologies の製品パイプライン分析2016] (コード:DATA70209150)販売に関する免責事項を必ずご確認ください。
★調査レポート[Biomar Microbial Technologies の製品パイプライン分析2016]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆